Primary intravitreal ranibizumab for myopic choroidial neovascularisation

Seminars in Ophthalmology

Volumn 26, Issue 2, 2011, Pages 52-54

  Qureshi, Farhan ^a,b   Saeed, M U ^a   Kamal, A ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

chorodial neovascularisation; Myopia; retina; VEGF

Indexed keywords

CEFUROXIME; CHLORAMPHENICOL; RANIBIZUMAB;

ADULT; AGED; ARTICLE; CENTRAL FOVEAL THICKNESS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANGIOGRAPHY; FUNDUS FLUORESCEIN ANGIOGRAPHY; HUMAN; MALE; MYOPIA; MYOPIC CHOROIDAL NEOVASCULARIZATION; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA EDEMA; RETINA FOVEA; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; THICKNESS; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; HUMANS; INTRAVITREAL INJECTIONS; MIDDLE AGED; MYOPIA; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 79953790175     PISSN: 08820538     EISSN: 17445205     Source Type: Journal    
DOI: 10.3109/08820538.2011.559515     Document Type: Article

References (24)

1. Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excises subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992;114:464-472.
2. Grossniklaus HE, Hutchinson AK, Capone A, et al. Clinicopathologic features of surgically excised choroidal neovascularmembranes. Ophthalmology 1994;101:1099-111 (Pubitemid 24183168)
3. Cohen SY, Laroche A, Leguen Y, et al . Etiology of choroidal neovascularization in young patients. Ophthalmology 1996;103(8):1241-1244. (Pubitemid 26282507)
4. Ohno-Matsui K, Yoshida T, Futagami S, et al. Patchy atrophy and lacquer cracks predispose to the development of choroidal neovascularisation in pathological myopia. Br J Ophthalmol 2003;87:570-3. (Pubitemid 36535327)
5. Nguyen QD, Shah S, Tatlipinar S, et al. Bevacizumab suppresses choroidal neovascularization caused by pathological myopia. Br J Ophthalmol 2005;89:1368-70. (Pubitemid 41638883)
6. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006;26:1093-4. (Pubitemid 44973239)
7. Yamamoto I, Rogers HA, Reichel E, et al. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularization secondary to pathological myopia. Br J Ophthalmol 2007;91:157-60. (Pubitemid 46202862)
8. Sakaguchi H, Ikuno Y, Gomi F, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-5. (Pubitemid 46202863)
9. Laud K, Spaide RF, Freund KB, et al. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab. Retina 2006;26:960-3. (Pubitemid 44547453)
10. Hernàndez-Rojas ML, Quiroz-Mercado H, Dalma-Weiszhausz J, et al. Short-term effects of intravitreal bevacizumab for subfoveal choroidal neovascularization in pathologic myopia. Retina 2007;27:707-12. (Pubitemid 47051766)
11. Mandal S, Venkatesh P, Sampangi R, et al. Intravitreal bevacizumab (Avastin) as primary treatment for myopic choroidal neovascularization. Eur J Ophthalmol 2007;17:620-6. (Pubitemid 47605773)
12. Rheaume M, Sebag M. Intravitreal bevacizumab for the treatment of chorodial neovascularisation associated with pathological myopia. Can J Ophthalmol. 2008; 43 (5):576-580.
13. Arias L, Planas N, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br. J. Ophthalmol. 2008;92:1035-1039.
14. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: Short-term results. Eye. (2009) 23, 334-338; doi:10.1038/sj.eye.6703052; published online 7 December 2007.
15. Chan WM, Lai TY, Liu DT, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: Six-month results of a prospective pilot study. Ophthalmology 2007;114:2190-6.
16. Ruiz-Moreno JM, Montero JA, et al. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448-451.
17. Wu PC, Chen YJ, Intravitreal injection of bevacizumab for myopic choroidal neovascularization: 1-year follow-up. Eye 2009 Jan 16 (epub).
18. Yasushi I, Sayanagi K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: One-year results. American Journal of Ophthal Mol 2009;147(1);94-100.
19. Gharbiya M, Allievi F, et al. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009;147:84-93.
20. Wong D, Li K. Avastin in myopic chorodial neovascularisation: Is age the limit. Br J Ophthalmol 2008;92(8):1011-12.
21. Silva RM, Ruiz-Moreno JM, Rosa P, Carneiro A, Nascimento J, Rito LF, Cachulo ML, Carvalheira F, Murta JN. Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results. Retina. 2010 Mar;30(3):407-12.
22. Lalloum F, Souied EH, Bastuji-Garin S, Puche N, Querques G, Glacet-Bernard A, Coscas G, Soubrane G, Leveziel N. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina. 2010 Mar;30(3):399-406.
23. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina. 2009 Jun;29(6):750-6.
24. Konstantinidis L, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009 Mar;247(3):311-8.